Intuitive Surgical’s (ISRG) Buy Rating Reaffirmed at BTIG Research

Intuitive Surgical (NASDAQ:ISRG)‘s stock had its “buy” rating reissued by BTIG Research in a research note issued on Tuesday, Benzinga reports. They presently have a $469.00 price target on the medical equipment provider’s stock. BTIG Research’s target price would suggest a potential upside of 27.90% from the company’s current price.

Other equities analysts have also issued research reports about the company. Bank of America dropped their price objective on Intuitive Surgical from $520.00 to $515.00 in a report on Friday, June 12th. Deutsche Bank Aktiengesellschaft dropped their price target on Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating on the stock in a research note on Tuesday, June 2nd. KeyCorp reiterated an “overweight” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Wall Street Zen lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $483.00 target price (down from $577.00) on shares of Intuitive Surgical in a report on Friday, July 17th. Twenty-two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $508.68.

Intuitive Surgical Stock Performance

ISRG stock opened at $366.70 on Tuesday. The stock has a market cap of $129.55 billion, a P/E ratio of 42.00, a PEG ratio of 2.77 and a beta of 1.47. Intuitive Surgical has a twelve month low of $328.57 and a twelve month high of $603.88. The company’s 50 day moving average is $380.66 and its two-hundred day moving average is $427.31.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The business had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. On average, equities research analysts predict that Intuitive Surgical will post 8.87 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Mark Brosius sold 77 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total value of $28,918.89. Following the transaction, the executive vice president owned 881 shares of the company’s stock, valued at approximately $330,877.17. The trade was a 8.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 400 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the sale, the director owned 251 shares of the company’s stock, valued at $95,129. This trade represents a 61.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 11,635 shares of company stock worth $4,640,172. 0.60% of the stock is currently owned by company insiders.

Institutional Trading of Intuitive Surgical

Several hedge funds have recently made changes to their positions in the company. Brighton Jones LLC increased its position in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock worth $1,916,000 after purchasing an additional 731 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Intuitive Surgical by 3.8% in the second quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after buying an additional 34 shares in the last quarter. Schnieders Capital Management LLC. boosted its stake in shares of Intuitive Surgical by 38.0% in the second quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock valued at $529,000 after buying an additional 268 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in Intuitive Surgical during the second quarter worth $200,000. Finally, Main Street Financial Solutions LLC grew its holdings in Intuitive Surgical by 92.4% during the second quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock worth $1,592,000 after acquiring an additional 1,407 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.